Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags
NCT ID
NCT06014502
TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase
Phase 1
Date Added
2023-08-28
Location
Louisiana, United States
Texas, United States
Prior IO Allowed
No
CRC-directed
No
Status
Recruiting
Drugs
IMGS-001
Tags
MSI-H/ MMRd
NCT ID
NCT06013111
TitleAn Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors Phase
Phase 1
Date Added
2023-08-28
Location
China
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06010901
TitleA Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. Phase
Phase 1
Date Added
2023-08-25
Location
China
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06011772
TitleA Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer Phase
Early Phase 1
Date Added
2023-08-25
Location
New York, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Suspended
Drugs
fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06008119
TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Phase
Phase 3
Date Added
2023-08-23
Location
China
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06006923
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer Phase
Phase 2
Date Added
2023-08-23
Location
California, United States
Florida, United States
Illinois, United States
Pennsylvania, United States
Washington, United States
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags
MSI-H/ MMRd
NCT ID
NCT05999812
TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer Phase
Phase 2
Date Added
2023-08-21
Location
Texas, United States
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
all trans Retinoic Acid, Atezolizumab, Bevacizumab
Tags
MSS/ MMRp
NCT ID
NCT05990543
TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer Phase
Phase 1
Date Added
2023-08-14
Location
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Not yet recruiting
Drugs
Nelmastobart and Capecitabine
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05976906
TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors Phase
Phase 1
Date Added
2023-08-04
Location
China
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05973487
TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Phase
Phase 1
Date Added
2023-08-03
Location
Arizona, United States
California, United States
Connecticut, United States
Florida, United States
Illinois, United States
Kentucky, United States
Michigan, United States
Minnesota, United States
New York, United States
North Carolina, United States
Ohio, United States
Oklahoma, United States
Oregon, United States
Pennsylvania, United States
Tennessee, United States
Texas, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp